Novartis AG ADR (NVS)vsFirst Tracks Biotherapeutics (TRAX)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
TRAX
First Tracks Biotherapeutics
$16.14
-10.78%
HEALTHCARE · Cap: $615.50M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
TRAX
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for TRAX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TRAX
The strongest argument for TRAX centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TRAX
The primary concerns for TRAX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while TRAX is a value play — different risk/reward profiles.
TRAX is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 25/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →First Tracks Biotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
First Tracks Biotherapeutics (Ticker: TRAX) is an innovative biotechnology company focused on advancing the development of targeted therapeutics for chronic diseases. With a strong emphasis on harnessing cutting-edge research and proprietary technology, TRAX aims to create transformative treatments that address unmet medical needs. The company is committed to improving patient outcomes through its novel drug candidates, which are designed to be effective and safe. As TRAX continues to progress through clinical trials, it seeks strategic partnerships to enhance its development pipeline and expand its market reach.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?